Výsledky vyhledávání - "Joachim Stangier"

Anticoagulant Effects of Dabigatran in Paediatric Patients Compared with Adults: Combined Data from Three Paediatric Clinical Trials

Autor: Igor Tartakovsky, Martina Brueckmann, Lesley G. Mitchell, Fenglei Huang, Hugo Maas, Joachim Stangier, Savion Gropper, Jacqueline Halton

Publikováno v: Thrombosis and Haemostasis

Background Physiological age-related changes in the haemostatic and coagulation systems result in differing anticoagulant assay responses to standard anticoagulants. Therefore, we investigated the response of anticoagulant assays to dabigatran etexil

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a27e96bc21fabfd6d20bb01ab186fc46
https://doi.org/10.1055/s-0038-1668132

Zobrazit plný text záznamu

Idarucizumab for Dabigatran Reversal — Full Cohort Analysis

Publikováno v: New England Journal of Medicine, 377(5), 431-441

Idarucizumab, a monoclonal antibody fragment, was developed to reverse the anticoagulant effect of dabigatran.We performed a multicenter, prospective, open-label study to determine whether 5 g of intravenous idarucizumab would be able to reverse the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e177ff62563c812b9685cde74dbc698
https://doi.org/10.1056/nejmoa1707278

Zobrazit plný text záznamu

Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studies

Autor: Paul A. Reilly, Ippei Ikushima, Akiko Harada, Benjamin Lang, Susumu Imazu, Joachim Stangier, Wouter Haazen, Viktoria Moschetti, Stephan Glund, Steven Ramael, Stephen Norris

Publikováno v: British Journal of Clinical Pharmacology. 83:1815-1825

Aims Idarucizumab, a humanized monoclonal anti-dabigatran antibody fragment, is effective in emergency reversal of dabigatran anticoagulation. Pre-existing and treatment-emergent anti-idarucizumab antibodies (antidrug antibodies; ADA) may affect the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e0a19804bbad6d698183eea75b574082
https://doi.org/10.1111/bcp.13269

Zobrazit plný text záznamu

Idarucizumab does not have procoagulant effects: Assessment of thrombosis biomarkers in healthy volunteers

Autor: Marina De Smet, Akiko Harada, Paul A. Reilly, Viktoria Moschetti, Joachim Stangier, Stephan Glund, Fredrik Grünenfelder, Steven Ramael, Ippei Ikushima, Michael Schmohl, Susumu Imazu

Publikováno v: Thrombosis and Haemostasis. 117:269-276

SummaryIdarucizumab, a humanised monoclonal antibody fragment, binds dabigatran with high affinity and immediately, completely and sustainably reverses dabigatran-induced changes on blood coagulation. The present analysis focuses on the evaluation of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d7cfa3ed8b89c9e7d1667f8724c673c
https://doi.org/10.1160/th16-05-0385

Zobrazit plný text záznamu

Idarucizumab, a specific reversal agent for dabigatran: mode of action, pharmacokinetics and pharmacodynamics, and safety and efficacy in phase 1 subjects

Autor: Stephan Glund, Joanne van Ryn, Oliver Grottke, Paul A. Reilly, Joachim Stangier

Publikováno v: The American Journal of Emergency Medicine. 34:26-32

The direct oral anticoagulants (DOACs) provide a number of clinical advantages over vitamin K antagonists for the treatment of thromboembolism, including improved efficacy and safety, as well as no need for regular monitoring of anticoagulant effect.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a2d1ae032403f0e266d75f0611cd87e
https://doi.org/10.1016/j.ajem.2016.09.050

Zobrazit plný text záznamu

Pharmacokinetics of idarucizumab and its target dabigatran in patients requiring urgent reversal of the anticoagulant effect of dabigatran

Autor: Paul A. Reilly, Kelly Coble, Stephan Glund, Dietmar Gansser, Karin Hoermann, Charles V. Pollack, Joachim Stangier

Publikováno v: Journal of Thrombosis and Haemostasis

Background Idarucizumab is a monoclonal antibody fragment that reverses dabigatran anticoagulation. Pharmacokinetics (PK) of idarucizumab have been described in healthy, elderly, or renally impaired (RI) volunteers, but PK data in patients are lackin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de0d8d8392d5dd9224ac5c8c9ef501dc
https://pubmed.ncbi.nlm.nih.gov/31050868

Zobrazit plný text záznamu

Idarucizumab for Dabigatran Reversal

Autor: Elaine M. Hylek, Joachim Stangier, Bushi Wang, Jeffrey I. Weitz, Menno V. Huisman, Robert Dubiel, Thorsten Steiner, Paul A. Reilly, John W. Eikelboom, Chak Wah Kam, Frank W. Sellke, Richard A. Bernstein, Peter Verhamme, Jerrold H. Levy, Jörg Kreuzer, Pieter W. Kamphuisen, Stephan Glund, Charles V. Pollack

Publikováno v: New England Journal of Medicine, 373(6), 511-520. MASSACHUSETTS MEDICAL SOC
New England Journal of Medicine, 373(6), 511-520

BACKGROUNDSpecific reversal agents for non-vitamin K antagonist oral anticoagulants are lacking. Idarucizumab, an antibody fragment, was developed to reverse the anticoagulant effects of dabigatran.METHODSWe undertook this prospective cohort study to

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0269d7204ef00f9f7e34842d006749f6
https://doi.org/10.1056/NEJMoa1502000

Zobrazit plný text záznamu

Measurement of dabigatran plasma concentrations by calibrated thrombin clotting time in comparison to LC-MS/MS in human volunteers on dialysis

Autor: Michael Schmohl, Dietmar Gansser, Viktoria Moschetti, Joachim Stangier

Publikováno v: Thrombosis Research. 135:532-536

article i nfo ® Thrombin Inhibitors assay LC-MS/MS end-stage renal disease Introduction: Dabigatran etexilate isan oral direct thrombininhibitor. Although routine anticoagulation monitor- ing with dabigatran is not usually required, a simple and pre

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c03754fafe2be91f40ef20473d59df78
https://doi.org/10.1016/j.thromres.2014.12.021

Zobrazit plný text záznamu

Restarting Dabigatran Etexilate 24 h After Reversal With Idarucizumab and Redosing Idarucizumab in Healthy Volunteers

Autor: Dietmar Gansser, Stephan Glund, Marina De Smet, Benjamin Lang, Joanne van Ryn, Wouter Haazen, Joachim Stangier, Stephen Norris, Michael Schmohl, Jörg Kreuzer, Viktoria Moschetti, Paul A. Reilly

Publikováno v: Journal of the American College of Cardiology. 67:1654-1656

Idarucizumab is a specific reversal agent that rapidly neutralizes dabigatran’s anticoagulant activity [(1–3)][1]. We investigated restoration of dabigatran anticoagulation 24 h after idarucizumab treatment and the safety and effectiveness of a s

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::369005b2b6f314aecda19b67a3183820
https://doi.org/10.1016/j.jacc.2016.01.043

Zobrazit plný text záznamu

Safety, pharmacokinetics and pharmacodynamics of idarucizumab, a specific dabigatran reversal agent in healthy Japanese volunteers: a randomized study

Autor: Ippei Ikushima, Michael Schmohl, Masahiro Yasaka, Paul A. Reilly, Dietmar Gansser, Akiko Harada, Joachim Stangier, Atsushi Taniguchi, Stephen Norris, Susumu Imazu

Publikováno v: Research and Practice in Thrombosis and Haemostasis

Essentials Idarucizumab, a monoclonal antibody fragment, binds dabigatran with high affinity and specificity. In this phase 1 trial, healthy Japanese males received idarucizumab alone or with dabigatran. Idarucizumab achieved immediate, complete and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6236fbf177908e2ec54426cab1c032fb
https://pubmed.ncbi.nlm.nih.gov/30046691

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání